Genetically engineered vaccines: An overview

Plasmid

Volumn 39, Issue 2, 1998, Pages 100-113

  Dertzbaugh, Mark T ^a  

^a Dept of Immunol and Molec Biology Bldg 1425 U States Army Med R   (United States)

Author keywords

DNA vaccines; Review; Synthetic vaccines; Vaccines

Indexed keywords

ADDRESSIN; ADJUVANT; ALCOHOL OXIDASE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIGEN; AROMATIC AMINO ACID; BETA LACTAM ANTIBIOTIC; CHOLERA TOXIN; CYTOKINE; DNA; DNA VACCINE; EPITOPE; FORMALDEHYDE; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; INACTIVATED VACCINE; LACTOSE; LIVE VACCINE; MALTOSE BINDING PROTEIN; NEUTRALIZING ANTIBODY; PEPTIDE; RECOMBINANT PROTEIN; RNA; THIOREDOXIN; THYMIDINE KINASE; TOXIN; TOXOID; UNINDEXED DRUG; VACCINE; VIRUS DNA;

ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTERIOPHAGE; BACTERIUM; BACULOVIRUS; DRUG DELIVERY SYSTEM; GENETIC ENGINEERING; GENOME; GOOD MANUFACTURING PRACTICE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; PROTEIN EXPRESSION; REPLICON; REVIEW; VIRUS GENOME; YEAST;

BACTERIA (MICROORGANISMS); DNA VIRUSES; UNIDENTIFIED BACULOVIRUS;

EID: 0031919480     PISSN: 0147619X     EISSN: None     Source Type: Journal    
DOI: 10.1006/plas.1997.1329     Document Type: Review

References (66)

1. Anderson G. W. Jr., Leary S. E., Williamson E. D., Titball R. W., Welkos S. L., Worsham P. L., Friedlander A. M. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains ofYersinia pestis. Infect. Immun. 64:1996;4580-4585.
2. Anspach F. B., Hilbeck O. Removal of endotoxin by affinity sorbents. J. Chrom. A. 711:1995;81-92.
3. Current Protocols in Molecular Biology. 1995;Wiley, New York.
4. Bost K. L., Holton R. H., Clements J. D. In vivo treatment with antibodies against IL-13 dramatically inhibits mucosal and systemic humoral responses in mice orally immunized with the B subunit ofE. coli. Clin. Immunol. Immunopathol. 76:1995.
5. Broekhuijsen M. P., van Rijn J. M., Blom A. J., Pouwels P. H., Enger-Valk B. E., Brown F., Francis M. J. Fusion proteins with multiple copies of the major antigenic determinant of foot-and-mouth disease virus protect both the natural host and laboratory animals. J. Gen.Virol. 68:1987;3137-3143.
6. Butler, V. A. 1996, Points to Consider on Plasmid DNA Vaccines for Preventive Infectious Disease Indications. Food and Drug Administration, Rockville, MD.
7. Carbonell L. F., Klowden M. J., Miller L. K. Baculovirus-mediated expression of bacterial genes in dipteran and mammalian cells. J. Virol. 56:1985;153-160.
8. Chang S. P., Case S. E., Gosnell W. L., Hashimoto A., Kramer K. J., Tam L. Q., Hashiro C. Q., Nikaido C. M., Gibson H. L., Lee-Ng C. T., Barr P. J., Yokota B. T., Hut G. S. A recombinant baculovirus 42-kilodalton C-terminal fragment ofPlasmodium falciparumAotus. Infect. Immun. 64:1996;253-261.
9. Chow Y. H., Huang W. L., Chi W. K., Chu Y. D., Tao M. H. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J. Virol. 71:1997;169-178.
10. Clare J. J., Rayment F. B., Ballantine S. P., Sreekrishna K., Romanos M. A. High-level expression of tetanus toxin fragment C inPichia pastoris. BioTechnology. 9:1991;455-460.
11. Clayton M. A., Clayton J. M., Brown D. R., Middlebrook J. L. Protective vaccination with a recombinant fragmentof Clostridium botulinumEscherichia coli. Infect. Immun. 63:1995;2738-2742.
12. Corbel M. J. Reasons for instability of bacterial vaccines. Dev. Biol. Stand. 87:1996;113-124.
13. Cregg J. M., Vedvick T. S., Raschke W. C. Recent advances in the expression of foreign genes inPichia pastoris. BioTechnology. 11:1993;905-910.
14. De Wilde M. J., Romanos M. A., Clare J. J., Beesley K. M., Rayment F. B., Ballantine S. P., Makoff A. J., Dougan G., Fairweather N. F., Charles I. G. Yeast as a host for the production of macromolecules of prophylactic or therapeutic interest in human health care. Bioprocess Technol. 5:1990;479-504.
15. Dertzbaugh M. T., Elson C. O. Cholera toxin as a mucosal adjuvant. Spriggs D. R., Koff W. C. Topics in Vaccine Adjuvant Research. 1991;119-131.
16. Dertzbaugh M. T., Elson C. O. Comparative effectiveness of the cholera toxin B subunit and alkaline phosphatase as carriers for oral vaccines. Infect. Immun. 61:1993;48-55.
17. Donnelly J. J., Ulmer J. B., Shiver J. W., Liu M. A. DNA vaccines. Annu. Rev. Immunol. 15:1997;617-648.
18. Dorner F. An overview of vaccine vectors. Dev. Biol. Stand. 84:1995;23-32.
19. Dunn S. J., Fiore L., Werner R. L., Cross T. L., Broome R. L., Ruggeri F. M., Greenberg H. B. Immunogenicity, antigenicity, and protection efficacy of baculovirus expressed VP4 trypsin cleavage products, VP5(1) and VP8 from rhesus rotavirus. Arch. Virol. 140:1995;1969-1978.
20. Feighny R., Burrous J., Putnak R. Dengue type-2 virus envelope protein made using recombinant baculovirus protects mice against virus challenge. Am. J. Trop. Med. Hyg. 50:1994;322-328.
21. Frolov I., Frolova E., Schlesinger S. Sindbis virus replicons and Sindbis virus: Assembly of chimeras and of particles deficient in virus RNA. J. Virol. 71:1997;2819-2829.
22. Gupta R. K., Griffin P. Jr., Chang A. C., Rivera R., Anderson R., Rost B., Cecchini D., Nicholson M., Siber G. R. The role of adjuvants and delivery systems in modulation of immune response to vaccines. Adv. Exp. Med. Biol. 397:1996;105-113.
23. Gupta R. K., Siber G. R. Adjuvants for human vaccines - Current status, problems and future prospects. Vaccine. 13:1995;1263-1276.
24. Haanes E. J., Guimond P., Wardley R. The bovine parainfluenza virus type-3 (BPIV-3) hemagglutinin/neuraminidase glycoprotein expressed in baculovirus protects calves against experimental BPIV-3 challenge. Vaccine. 15:1997;730-738.
25. Hajishengallis G., Hollingshead S. K., Koga T., Russell M. W. Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J. Immunol. 154:1995;4322-4332.
26. Heath A. W., Hadden J. W. Cytokines and the rational choice of immunological adjuvants. Cancer Biother. 9:1994;1-6.
27. Hoiseth S., Stocker B. A. D. Aromatic-dependentSalmonella typhimurium. Nature. 291:1980;238-239.
28. Isobe H., Moran T., Li S., Young A., Nathenson S., Palese P., Bona C. Presentation by a major histocompatibility complex class I molecule of nucleoprotein peptide expressed in two different genes of an influenza virus transfectant. J. Exp. Med. 181:1995;203-213.
29. Jones L. D., Williams T., Bishop D., Roy P. Baculovirus-expressed nonstructural protein NS2 of bluetongue virus induces a cytotoxic T-cell response in mice which affords partial protection. Clin. Diagn. Lab. Immunol. 4:1997;297-301.
30. Jones T., Stern A., Lin R. Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant. Eur. J. Clin. Microbiol. Infect. Dis. 13:1994;S47-53.
31. Kraal G., Mebius R. E. High endothelial venules: Lymphocyte traffic control and controlled traffic. Adv. Immunol. 65:1997;347-395.
32. Lakey D. L., Treanor J. J., Betts R. F., Smith G. E., Thompson J., Sannella E., Reed G., Wilkinson B. E., Wright P. F. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J. Infect. Dis. 174:1996;838-841.
33. Lanford R. E., Luckow V., Kennedy R. C., Dreesman G. R., Notvall L., Summers M. D. Expression and characterization of hepatitis B virus surface antigen polypeptides in insect cells with a baculovirus expression system. J. Virol. 63:1989;1549-1557.
34. Levine M. M., Kaper J. B. Live oral vaccines against cholera: An update. Vaccine. 11:1993;207-212.
35. Lin R., Tarr P. E., Jones T. C. Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Clin. Infect. Dis. 21:1995;1439-1449.
36. Lindberg A. A. The history of live bacterial vaccines. Dev. Biol. Stand. 84:1995;211-219.
37. Luckow V. A. Baculovirus systems for the expression of human gene products. Curr. Opin. Biotechnol. 4:1993;564-572.
38. Marin M. S., Martin Alonso J. M., Perez Ordoyo Garcia L. I., Boga J. A., Arguello-Villares J. L., Casais R., Venugopal K., Jiang W., Gould E. A., Parra F. Immunogenic properties of rabbit haemorrhagic disease virus structural protein VP60 expressed by a recombinant baculovirus: An efficient vaccine. Virus Res. 39:1995;119-128.
39. Marinaro, M. Boyaka, P. N. Jackson, R. J. Finkelman, F. D. Gately, M. K. Kiyono, H. McGhee, J. R. 1996, Mucosal administration of rmIL-12 to mice modulates Th2-type responses induced by an oral vaccine, FASEB J. 10, 1036.
40. McAleer W. J., Buynak E. B., Maigetter R. Z., Wampler D. E., Miller W. J., Hilleman M. R. Human hepatitis B vaccine from recombinant yeast. Nature. 307:1984;178-180.
41. McCormick A. L., Thomas M. S., Heath A. W. Enhancement of immunogenicity of recombinant antigens by production of a cytokine-antigen fusion protein for vaccination. Biochem. Soc. Trans. 25:1997.
42. Medaglini D., Pozzi G., King T. P., Fischetti V. A. Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacteriumStreptococcus gordonii. Proc. Natl. Acad. Sci. USA. 92:1995;6868-6872.
43. Nohria A., Rubin R. H. Cytokines as potential vaccine adjuvants. Biotherapy. 7:1994;261-269.
44. Plana Duran J., Climent I., Sarraseca J., Urniza A., Cortes E., Vela C., Casal J. I. Baculovirus expression of proteins of porcine reproductive and respiratory syndrome virus strain Olot/91. Involvement of ORF3 and ORF5 proteins in protection. Virus Genes. 14:1997;19-29.
45. Porter D. C., Wang J., Moldoveanu Z., McPherson S., Morrow C. D. Immunization of mice with poliovirus replicons expressing the C-fragment of tetanus toxin protects against lethal challenge with tetanus toxin. Vaccine. 15:1997;257-264.
46. Pouwels P. H., Leer R. J., Boersma W. J. The potential ofLactobacillus. J. Biotechnol. 44:1996;183-192.
47. Pozzi G., Oggioni M. R., Manganelli R., Fischetti V. A. Expression of M6 protein geneof Streptococcus pyogenesStreptococcus gordonii. Res. Microbiol. 143:1992;449-457.
48. Rott L. S., Briskin M. J., Andrew D. P., Berg E. L., Butcher E. C. A fundamental subdivision of circulating lymphocytes defined by adhesion to mucosal addressin cell adhesion molecule-1. Comparison with vascular cell adhesion molecule-1 and correlation with beta 7 integrins and memory differentiation. J. Immunol. 156:1996;3727-3736.
49. Roy P., Bishop D. H., Howard S., Aitchison H., Erasmus B. Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge. J. Gen. Virol. 77:1996;2053-2057.
50. Sato Y., Roman M., Tighe H., Lee D., Corr M., Nguyen M., Silverman G. J., Lotz M., Carson D. A., Raz E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 273:1996;352-354.
51. Schutze-Redelmeier M. P., Gournier H., Garcia-Pons F., Moussa M., Joliot A. H., Volovitch M., Prochiantz A., Lemonnier F. A. Introduction of exogenous antigens into the MHC class I processing and presentation pathway byDrosophila antennapedia. J. Immunol. 157:1996;650-655.
52. Shoup D. I., Jackwood D. J., Saif L. J. Active and passive immune responses to transmissible gastroenteritis virus (TGEV) in swine inoculated with recombinant baculovirus-expressed TGEV spike glycoprotein vaccines. Am. J. Vet. Res. 58:1997;242-250.
53. Studier F. W., Rosenberg A. H., Dunn J. J., Dubendorff J. W., Fuerst T. R., Niles E. G., Moss B. Use of T7 RNA polymerase to direct expression of cloned genes. Methods: Enzymol. Companion Methods. 185:1990;60-89.
54. Sumner J. W., Sims K. G., Jones D. C., Anderson B. E. Protection of guinea-pigs from experimental Rocky Mountain spotted fever by immunization with baculovirus-expressedRickettsia rickettsii. Vaccine. 13:1995;29-35.
55. Tidswell M., Pachynski R., Wu S. W., Qiu S. Q., Dunham E., Cochran N., Briskin M. J., Kilshaw P. J., Lazarovits A. I., Andrew D. P., Butcher E. C., Yednock T. A., Erle D. J. Structure-function analysis of the integrin beta 7 subunit: Identification of domains involved in adhesion to MAdCAM-1. J. Immunol. 159:1997;1497-1505.
56. Tschopp J. F., Cregg J. M. Heterologous gene expression in methylotrophic yeast. BioTechnology. 18:1991;305-322.
57. Uzendoski K., Kantor J. A., Abrams S. I., Schlom J., Hodge J. W. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: Induction and potentiation of antitumor responses. Hum. Gene Ther. 8:1997;851-860.
58. Valenzuela P., Medina A., Rutter W. J., Ammerer G., Hall B. D. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature. 298:1982;347-350.
59. Van Doorne H. Sorption of bacterial endotoxin and retention of bacteria by positively charged membrane filters. J. Parent. Sci. Tech. 47:1993;192-198.
60. Venugopal K., Jiang W. R., Gould E. A. Immunity to St. Louis encephalitis virus by sequential immunization with recombinant vaccinia and baculovirus derived PrM/E proteins. Vaccine. 13:1995;1000-1005.
61. Vlak J. M., Keus R. J. Baculovirus expression vector system for production of viral vaccines. Adv. Biotechnol. Processes. 14:1990;91-128.
62. Vogel F. R. Immunologic adjuvants for modern vaccine formulations. Ann. N.Y. Acad. Sci. 754:1995;153-160.
63. Weary M., Pearson F. A manufacturer's guide to depyrogenation. BioPharmacology. April:1988;22-29.
64. Wells J. M., Wilson P. W., Norton P. M., Gasson M. J., Le Page R. W. Lactococcus lactis. Mol. Microbiol. 8:1993;1155-1162.
65. Yokoyama N., Maeda K., Mikami T. Recombinant viral vector vaccines for the veterinary use. J. Vet. Med. Sci. 59:1997;311-322.
66. Zhu X., Wu S., Letchworth G. J. R. Yeast-secreted bovine herpesvirus type 1 glycoprotein D has authentic conformational structure and immunogenicity. Vaccine. 15:1997;679-688.